EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study

Michele Mondoni, Francesco Varone, Fabrizio Luppi, Paolo Cameli, Stefania Cerri, Mariangela Valentina Puci, Jacopo Cefalo, Simone Contino, Alessia Martini, Bruno Iovene, Giacomo Sgalla, Giovanni Franco und 10 weitere

Lung · 2025-12 · 203 (1)

DOI: 10.1007/s00408-025-00832-4 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Lung, online erschienen am 08.07.2025. Verfasst von Michele Mondoni und 21 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Via A. Di Rudinì N.8, 20142, Milan, Ital…. Hauptthemen laut MEDLINE: Indoles, Pulmonary Fibrosis, Lung, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Pulmonary fibrosis is defined as progressive based on the combination of radiological, clinical, and functional criteria. Nintedanib can reduce the rate of lung function decline, but no data are available on its effectiveness to hamper disease progression evaluated by these criteria. The primary aim of the study was to assess the number of patients with progressive pulmonary fibrosis (PPF) who no longer meet progression criteria after one year of treatment with nintedanib. METHODS: A retrospective, observational, multicenter study was carried out in Italy. RESULTS: 172 patients (91 (52.9%) males) with PPF were recruited, and 135 (78.5%) completed one year of treatment. After one year, 87 (64.4%) patients no longer met INBUILD progression criteria, while 107 (79.3%) did not meet 2022 ATS/ERS/JRS/ALAT guidelines criteria. Nintedanib hampered progression regardless of inclusion criteria, radiological pattern, and etiological diagnosis. Forced vital capacity (FVC) decline was significantly higher in the 12 months before than in those of treatment (mean, SD): 2512.3 (863.2) ml vs. 2313.6 (821.9) ml; p < 0.0001; 2313.6 (821.9) vs. 2335.7 (865.1); p = 0.82). FVC decline was significantly higher in the year before than in the year of treatment regardless of radiological pattern, etiological subtypes, and respiratory function. Diarrhea (mostly mild) was the most frequent adverse event (51.7%). A permanent discontinuation of the drug was recorded in 15 (9%) patients. CONCLUSION: Nintedanib is effective and safe in patients with PPF. Besides slowing lung function decline, it hampers progression regardless of etiological diagnosis, radiological pattern, respiratory function, and baseline inclusion criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesPulmonary FibrosisLungIdiopathic Pulmonary FibrosisHumansMaleFemaleDisease ProgressionRetrospective StudiesMiddle AgedAgedItalyVital CapacityTreatment Outcome

Stichwörter der Autor:innen

AntifibroticFVCNintedanibPPFProgression criteriaProgressive fibrosisUIP

Substanzen

nintedanibIndoles

Autor:innen und Institutionen

  • Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Via A. Di Rudinì N.8, 20142, Milan, Italy. michele.mondoni@unimi.it.
  • Fondazione Policlinico Gemelli IRCSS, Rome, Italy.
  • Respiratory Unit, Fondazione IRCCS "San Gerardo dei Tintori", Università degli Studi di Milano Bicocca, Monza, Italy.
  • Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
  • Respiratory Disease Unit, University Hospital of Modena, Modena, Italy.
  • Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Zitieren

APA

Mondoni, M., Varone, F., Luppi, F., Cameli, P., Cerri, S., Puci, M. V., Cefalo, J., Contino, S., Martini, A., Iovene, B., Sgalla, G., Franco, G., Zanini, U., Pianigiani, T., Dilroba, A., Puggioni, D., Patsoura, A., Mosole, B., Torre, O., …, & Sotgiu, G. (2025). Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study. Lung, 203(1). https://doi.org/10.1007/s00408-025-00832-4

Vancouver

Mondoni M, Varone F, Luppi F, Cameli P, Cerri S, Puci MV, et al. Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study. Lung. 2025;203(1). doi:10.1007/s00408-025-00832-4

BibTeX
@article{Mondoni2025,
  author = {Mondoni, Michele and Varone, Francesco and Luppi, Fabrizio and Cameli, Paolo and Cerri, Stefania and Puci, Mariangela Valentina and Cefalo, Jacopo and Contino, Simone and Martini, Alessia and Iovene, Bruno and Sgalla, Giacomo and Franco, Giovanni and Zanini, Umberto and Pianigiani, Tommaso and Dilroba, Akter and Puggioni, Daniele and Patsoura, Athina and Mosole, Benedetta and Torre, Olga and Bargagli, Elena and Richeldi, Luca and Sotgiu, Giovanni},
  title = {Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study},
  journal = {Lung},
  year = {2025},
  volume = {203},
  number = {1},
  doi = {10.1007/s00408-025-00832-4}
}
Kostenlos starten →